Werewolf Therapeutics Stock Ten Year Return
| HOWL Stock | USD 2.00 0.10 5.26% |
Werewolf Therapeutics fundamentals help investors to digest information that contributes to Werewolf Therapeutics' financial success or failures. It also enables traders to predict the movement of Werewolf Stock. The fundamental analysis module provides a way to measure Werewolf Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Werewolf Therapeutics stock.
Werewolf | Ten Year Return |
Werewolf Therapeutics Company Ten Year Return Analysis
Werewolf Therapeutics' Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
More About Ten Year Return | All Equity Analysis
Ten Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Werewolf Ten Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Werewolf Therapeutics is extremely important. It helps to project a fair market value of Werewolf Stock properly, considering its historical fundamentals such as Ten Year Return. Since Werewolf Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Werewolf Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Werewolf Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Ten Year Fund Return indicator can give a sense of overall fund long-term potential, it is recommended to compare funds performances against other similar funds or market benchmarks for the same 10-year interval.
| Competition |
Werewolf Return On Tangible Assets
Return On Tangible Assets |
|
Based on the latest financial disclosure, Werewolf Therapeutics has a Ten Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Werewolf Ten Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Werewolf Therapeutics' direct or indirect competition against its Ten Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics of similar companies.Werewolf Therapeutics is currently under evaluation in ten year return category among its peers.
Werewolf Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (19.55) % | ||||
| Current Valuation | 3.08 M | ||||
| Shares Outstanding | 44.56 M | ||||
| Shares Owned By Insiders | 6.11 % | ||||
| Shares Owned By Institutions | 72.60 % | ||||
| Number Of Shares Shorted | 1.23 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 26.32 X | ||||
| Revenue | 19.94 M | ||||
| Gross Profit | (37.36 M) | ||||
| EBITDA | (32.47 M) | ||||
| Net Income | (37.37 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 51.92 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 2.04 X | ||||
| Cash Flow From Operations | (32.61 M) | ||||
| Short Ratio | 0.99 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 45 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 89.13 M | ||||
| Total Asset | 174.83 M | ||||
| Retained Earnings | (344.07 M) | ||||
| Working Capital | 118.99 M | ||||
| Net Asset | 174.83 M |
About Werewolf Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Werewolf Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Werewolf Therapeutics Piotroski F Score and Werewolf Therapeutics Altman Z Score analysis. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.